United States
Germany
Japan
United Kingdom
China
AASS - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
| Format | Lentiviral plasmids |
| Vector | pGFP-C-shLenti |
RNAi
Aass - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
| Format | Lentiviral plasmids |
| Vector | pGFP-C-shLenti |
AASS - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
| Format | Retroviral plasmids |
| Vector | pRS |
Aass - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
| Format | Retroviral plasmids |
| Vector | pRS |
Aass - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
| Format | Lentiviral plasmids |
| Vector | pGFP-C-shLenti |
Aass - Rat, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
| Format | Retroviral plasmids |
| Vector | pRS |
Aass (Mouse) - 3 unique 27mer siRNA duplexes - 2 nmol each
| Purity | HPLC purified |
| Number of Transfections | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
Aass (Rat) - 3 unique 27mer siRNA duplexes - 2 nmol each
| Purity | HPLC purified |
| Number of Transfections | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
AASS (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each
| Purity | HPLC purified |
| Number of Transfections | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
